CMC(SH:603122) Bei Jing Shang Bao·2025-12-03 11:56Core Viewpoint - The major shareholder of HeFu China, HeFu (Hong Kong) Holdings Limited, plans to reduce its stake by up to 2% amid a significant stock price increase, which has raised concerns among investors about potential market manipulation and the company's underlying fundamentals [1][3][4]. Group 1: Shareholder Actions - HeFu (Hong Kong) intends to reduce its holdings by a total of 7,961,100 shares, representing 2% of the company's total share capital, through block trades and centralized bidding [3]. - The planned reduction is motivated by the need to enhance operational funds, including financing for a magnetic resonance imaging navigation radiation therapy system project [3][4]. - Following the announcement, HeFu China's stock price dropped to its daily limit, closing at 23 CNY per share, a decrease of 10.02% on December 3 [3]. Group 2: Stock Performance - Since October 28, HeFu China's stock price has surged by 244.31%, despite multiple risk warnings and trading suspensions [3][5]. - The stock's market value increased by approximately 3.573 billion CNY during this period, while the value of the shares intended for reduction is about 183 million CNY [4]. Group 3: Financial Performance - HeFu China reported a net profit loss of approximately 12.39 million CNY for the first three quarters of the year, a significant decline compared to the previous year [5]. - Revenue for the same period was 549 million CNY, reflecting a year-on-year decrease of 22.8% due to changes in the macroeconomic environment and price reductions in the medical industry [5]. - The company anticipates further revenue declines in the coming years, projecting revenues of approximately 1.28 billion CNY, 1.093 billion CNY, and 939 million CNY for 2022, 2023, and 2024, respectively [5].